News archive 2008

12 December 2008
ABLYNX Reports Positive Phase Ib Results for its Anti-Thrombotic NANOBODY® ALX-0081

12 December 2008
Agendia’s MammaPrint® Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

11 December 2008
CHROMA announces Positive Phase II Efficacy Data for Novel Cancer Therapy Tosedostat in Acute Myeloid Leukaemia

10 December 2008
ABLYNX Reaches Milestone in TNF-alpha NANOBODY® Collaboration as Wyeth Pharmaceuticals Initiates Phase I

8 December 2008
ABLYNX Expands its Anti-Thrombotic Portfolio and Announces Initiation of a Phase I Study for ALX-0681

8 December 2008
Agendia Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium

4 December 2008
Symphogen receives milestone payment from Meiji Seika Kaisha

1 December 2008
Symphogen to Present Positive Preclinical Data on Sym004 Program for EGF-Receptor Positive Cancers

20 November 2008
Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project

5 November 2008
IDEA AG reports data of a 12-month comparative study of the targeted analgesic Diractin® (ketoprofen in Transfersome® gel) versus naproxen and gives development update

6 October 2008
INNATE PHARMA Swaps Products with NOVO NORDISK A/S to Obtain full Commercial Rights for IPH 2101, a monoclonal antibody in Phase I Cancer Clinical Trials

3 October 2008
AMT intends to incorporate additional data to its Marketing Authorization Dossier for Glybera®

22 September 2008
Acacia Pharma Starts First Clinical Trial with APD 405 for Nausea & Vomiting

18 September 2008
Agendia's MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines

18 September 2008
AMT Obtains License to Amgen’s GDNF Gene to Develop Treatment for Parkinson’s Disease with AMT’s Proprietary Gene Therapy Platform

4 September 2008
Agendia Launches TargetPrint for Breast Cancer Patients

4 September 2008
ABLYNX and Merck Serono Enter into an Agreement to Co-Discover and Co-Develop NANOBODIES®

29 July 2008
IDEA AG gives an update on the development of Diractin®, the targeted analgesic

24 July 2008
BG MEDICINE Announces Publication of Biomarker Signature of Atherosclerotic Plaque Rupture

17 July 2008
BG Medicine Closes $40 Million in Series D Financing

16 July 2008
SYMPHOGEN and BIOVITRUM have Initiated a Novel Treatment Study in Autoimmune Bleeding Disorder (ITP) Patients

16 July 2008
PIERIS - Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050

15 July 2008
AGENDIA and FERRER announces exclusive agreement for sales of cancer diagnostic services in four major european markets

19 June 2008
Santaris Pharma Appoints Søren Tulstrup as New President & CEO

18 June 2008
FlowCardia, Inc. Appoints Deborah DeFilippo CFO

13 June 2008
AMT prepares for submission of Marketing Authorization Dossier for AMT-011 (Glybera®)

11 June 2008
Symphogen Enters into Strategic Collaboration with Genentech for Antibody Therapeutics in Infectious Disease

10 June 2008
AMT makes important advance in the development of its gene therapy for Hemophilia B

30 May 2008
AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011

26 May 2008
AMT’s Cooperative Research and Development Agreement with NIH to Boost Production Capacity

22 May 2008
AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy

16 May 2008
Agendia’s lead product MammaPrint® receives important award from Innovation Platform

7 May 2008
IDEA AG receives two milestone payments ($37 million) from partner Alpharma

15 April 2008
Symphogen and Biovitrum Initiate a Second Clinical study with a Novel Treatment of Hemolytic Diseases

1 April 2008
BG Medicine announces collaboration with Takeda to Discover Biomarkers of High-Risk Atherosclerotic Plaque

27 March 2008
Pieris Raises EUR 25 million in Series B Financing Round

25 March 2008
Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer

19 February 2008
ABLYNX Receives Milestone Payment from NANOBODY® Discovery and Development Alliance

12 February 2008
BG Medicine and Copenhagen General Population Study Initiate Biomarker Discovery to Identify Individuals at High Risk of Heart Attack Within Four Years before Occurrence

12 February 2008
Gilde Healthcare Partners awarded European Venture Fundraising of the year

6 February 2008
Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody

5 February 2008
BG Medicine Acquires Exclusive Commercial Rights to Biomarker of Vascular Plaque Rupture from ACS Biomarker

Bottles with golden caps